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Abstract 
Succinyl-CoA:3-ketoacid CoA transferase (SCOT) is a key enzyme for ketone body utilization. Hereditary SCOT 
deficiency in humans (McKusick catalogue number 245050) is characterized by intermittent ketoacidotic attacks and 
permanent hyperketonemia. Since previously-available antibody to rat SCOT did not crossreact with human SCOT, we 
developed an antibody against recombinant human SCOT expressed in a bacterial system. The recombinant SCOT was 
insoluble except under denaturing conditions. Antibody raised to this polypeptide recognized enatured SCOT and proved 
useful for immunoblot analysis. On immunoblots, SCOT was easily detectable in control fibroblasts and lymphocytes but 
was detected neither in fibroblast extracts from four SCOT-deficient patients, nor in lymphocytes from two SCOT-deficient 
patients. These data indicate that immunoblot analysis is useful for diagnosis of SCOT deficiency in combination with 
enzyme assay. 
Kevwords: Inborn error of metabolism; Ketone body; Antibody; Immunoblot analysis; Coenzyme A transferase 
1. Introduction 
Abbreviations: SCOT, succinyl-CoA:3-ketoacid CoA trans- 
ferase; T2, mitochondrial cetoacetyl-CoA thiolase. 
* Corresponding author. Fax: + 81 58 2659011; E-mail: toshi- 
gif@umin.u-tokyo.ac.jp 
Department of Medical Genetics, The Hospital of Sick Chil- 
dren, Toronto, Canada 
Ketone bodies are important vectors of energy 
transfer from liver to extrahepatic tissues [1]. Ketosis 
is a normal physiologic response to fasting and other 
stresses but under some conditions such as uncon- 
trolled diabetes, severe ketoacidosis may develop. 
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The utilization of ketone bodies is mediated by two 
enzymes, succinyl-CoA:3-ketoacid CoA transferase 
(SCOT, EC 2.8.3.5) which catalyzes CoA transfer 
from succinyl-CoA to acetoacetate, and mitochon- 
drial acetoacetyl-CoA thiolase (T2, EC 2.3.1.9). 
Hereditary deficiency of either SCOT (McKusick 
catalogue number 245050) [2] or T2 (McKusick cata- 
logue number 203750) results in reduced ketolytic 
capacity, which manifests clinically by intermittent 
ketoacidotic attacks [3-10]. 
To aid the diagnosis of the hereditary deficiencies 
of ketolysis we have characterized the human T2 
polypeptide, cDNA and gene [10-13]. We have also 
cloned a human SCOT cDNA and have identified a 
nonsense mutation in one case of SCOT deficiency 
[14]. We showed that SCOT assay is diagnostically 
useful in lymphocytes, fibroblasts [8] and cultured 
amniocytes, but not in chorionic villi [15]. 
In unexplained hyperketotic states the analysis of 
organic compounds in plasma and urine does not 
allow a specific diagnosis for SCOT deficiency, al- 
though persistent hyperketonemia is believed to be 
characteristic of SCOT deficiency [3-8]. The assay 
of enzymatic activity is tedious and mutation analysis 
is expensive and should be limited to samples where 
SCOT is known to be deficient. Thus we developed a 
method for assaying semiquantatively gene products. 
In this paper, we describe the expression of recombi- 
nant human SCOT in bacteria, development of an 
antibody to this polypeptide and determination f the 
level of immunoreactive SCOT in normal and 
SCOT-deficient human cells. 
2. Materials and methods 
2.1. Antiserum to rat SCOT 
This polyclonal antiserum has been described [16]. 
2.2. Construction of a bacterial expression vector for 
a human SCOT cDNA 
A cDNA fragment spanning residues 115-1586, 
which includes the entire SCOT peptide less the 
mitochondrial targeting sequence, was amplified from 
a plasmid which contains the full-length SCOT 
cDNA. The following oligomers, which contain an 
XhoI cloning site (underlined) for ligation into the 
correct reading frame of the pET16b plasmid 
(Novagen) were used as sense primer: 5'- 
TGCCTCGAG 115 CATACCAAGTTTTATACAGAT-3' 
and as antisense primer: 5'-TTTCTCGI586AGCCTG - 
GTACAAATATCCATA-3'. PCR was performed as 
follows, using VENT DNA polymerase (New Eng- 
land BioLabs): 1 rain, 94°C; 2 min, 45°C and 3 min, 
72°C, for 25 cycles. Three clones were purified 
through a CsC1 density gradient and in vitro tran- 
scription and translation were performed according to 
the manufacturer's instructions (Novagen). Polypep- 
tides produced from each of the three clones showed 
the size predicted for the recombinant SCOT peptide. 
These three clones were mixed and used in further 
experiments. 
2.3. Expression and purification of recombinant 
SCOT protein 
Expression was performed according to the manu- 
facturer's instructions (Novagen). For one step purifi- 
cation of the recombinant SCOT protein in 6 M urea 
a His-Bind column (Novagen) was used. 
2.4. Development of rabbit antibody to recombinant 
human SCOT 
About 1 mg of purified recombinant SCOT was 
suspended in saline with urea, mixed with an equal 
volume of Complete Freund's Adjuvant and injected 
subcutaneously at three dorsal sites of a New Zealand 
white rabbit. Booster doses of 0.5 mg of recombinant 
SCOT in Incomplete Freund's Adjuvant were in- 
jected 2, 6 and 8 wk after the primary immunization. 
Immune serum was obtained 10 wk after the first 
immuni.zation and stored at -20°C until use. 
2.5. Cell lines and immunoblot analysis 
Cells from three previously-described SCOT-defi- 
cient patients were available: GS1 [7], GS2 and GS3 
[8,15]. GS2 and GS3 are siblings. Patient GS4 has 
not been reported but we confirmed SCOT deficiency 
enzymatically (1.6 and 2.3 nmol /min /mg protein; 
normal, 12.4 ___ 4.1 nmol/min per mg protein) 
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(Wanders et al., unpublished). Fibroblasts were cul- 
tured in Eagle's minimum essential medium contain- 
ing 10% fetal calf serum and routinely maintained at 
37°C in a 5% CO 2 atmosphere. Fibroblasts were 
harvested with 0.05% trypsin/0.01% EDTA, 2 days 
after reaching confluency. After three washes in 0.9% 
sodium chloride, cell pellets were stored at -80°C 
until use. 
Lymphocytes were isolated from heparinized blood 
samples by Ficoll gradient centrifugation (Pharmacia). 
Pellets of fibroblasts or lymphocytes were freeze- 
thawed and suspended in 40 mM sodium phosphate 
(pH 8.0), 0.1% Triton X-100. After sonication and 
centrifugation at 10000 X g for 10 min, the super- 
natant was used for enzyme assay and immunoblot 
analysis. 
2.6. Enzyme assay and immunoblot analysis 
SCOT assay was performed as described [17], with 
modifications [8]. Briefly, the assay mixture con- 
tained 30 mM acetoacetyl-CoA and 50 mM sodium 
succinate in 50 mM Tris-HC1 (pH 8.5), 10 mM 
MgCI 2, 4 mM iodoacetamide, and SCOT activity 
was measured spectrophotometrically s the decrease 
of acetoacetyl-CoA absorption at 303 nm. The molar 
extinction coefficient was 21 400 M-  ~ cm-  ~. Protein 
concentration was determined by the method of Lowry 
et al. [18] using bovine serum albumin as a standard. 
For immunoblots, human heart muscle was ob- 
tained at autopsy and stored at -80°C until use. 
Heart tissues from human and rat were homogenized 
in 10 volumes of 50 mM sodium phosphate (pH 8.0), 
0.1% Triton-X 100, and used for immunochemical 
analyses. Immunotitration was performed as de- 
scribed [19]. Briefly, aliquots of 4 /xl of heart tissue 
(3-5 mg protein/ml) were incubated with various 
amounts of antibody for 1 h at 4°C. After adjusting 
the volume to 80 /xl with 50 mM sodium phosphate 
(pH 8.0), 0.1% Triton X-100, we added 20 /xl of 
protein A Sepharose, containing about 20 /xg of 
Protein A (Sigma Chemicals, St. Louis, MO, USA) 
and the preparation was again incubated at 4°C for 1 
h. The preparation was centrifugated at 10 000 × g at 
4°C for 10 min and the supernatant was assayed for 
SCOT activity. Immunoblotting was performed ac- 
cording to Towbin et al. [20], using the ProtoBlot 
Western Blot AP System (Promega, Madison, WI). 
3. Result 
3.1. Immunoblot analysis using antibody to rat SCOT 
Extracts from rat and human heart muscles were 
studied by immunoblot analysis using antibody to rat 
SCOT prepared by Zhang et al. [16]. The rat SCOT 
polypeptide was detected but the antibody did not 
crossreact with human SCOT despite loading of up to 
200 /xg of human heart protein and the use of 
dilutions of antiserum as small as 1/100 (data not 
shown). 
3.2. Recombinant human SCOT. 
SCOT polypeptides expressed from each plasmid 
had the predicted molecular mass of ~ 55 kDa, 
showing that no premature termination mutation had 
been introduced uring PCR (data not shown). The 
results of the purification are presented in Fig. 1. As 
shown, the recombinant SCOT protein was insoluble 
in a solution of 5 mM imidazole, 500 mM NaC1, 20 
mM Tris-HC1 (pH 7.9), 0.1% NP40 and 1 mM PMSF 
(lane 2). We therefore solubilized the recombinant 
SCOT in the same solution with 6 M urea (lane 3), 
and purified this polypeptide by column chromatog- 
raphy with a His-Bind column (lane 7). Antibody was 
raised against his denatured recombinant SCOT pro- 
tein. 
3.3. Immunoblot analysis of antibody to human SCOT 
The polyclonal antiserum to recombinant human 
SCOT detected not only the human heart SCOT 
protein (Fig. 2, lanes 5-7), but also detected rat heart 
SCOT protein (lanes 1-3) with similar affinity. Both 
rat and human liver samples had no SCOT protein 
(lanes 4 and 8). Preimmune serum detected neither 
rat nor human SCOT protein (data not shown). 
3.4. Immunotitration a alysis 
We tested its interaction with nondenatured SCOT 
polypeptide, to see whether the antibodies would be 
useful for immunotitration and pulse-chase xperi- 
ment. As shown in Fig. 3, human SCOT activity 
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Fig. 1. Purification of recombinant SCOT protein. Samples from 
each of the induction and purification steps were subjected to 
electrophoresis on a 10% SDS-PAGE. Lanes 1-3 concern the 
sample preparation and about 1/6000 total amount was applied 
in each lane. Lanes 4-7 concern the chromatography on a His 
Bind column and about 1/1600 total amount was applied in each 
lane. Lane 1 is the starting material for purification, total ho- 
mogenate obtained 3 h after IPTG induction. Lane 2: supernatant 
of the homogenate with a solution of 5 mM imidazole, 500 mM 
NaCI, 20 mM Tris-HC1 (pH 7.9), 0.1% NP40 and 1 mM PMSF; 
lane 3: supernatant extracted from the pellets of the above 
homogenate with the same solution plus 6 M urea; lane 4: a 
pass-through fraction following application of the supernatant 
described for lane 3 to a His-Bind column; lanes 5 and 6: eluted 
solutions in washing with a solution of 5 mM imidazole, 500 mM 
NaC1, 20 mM Tris-HC1 (pH 7.9), and 6 M urea, and with a 
solution of 20 mM imidazole, 500 mM NaC1, 20 mM Tris-HCl 
(pH 7.9), and 6 M urea, respectively; lane 7: an eluted solution 
by 1 M imidazole, 500 mM NaCI, 20 mM Tris-HC1 (pH 7.9), and 
6 M urea. Arrows indicate the recombinant SCOT protein. 
could not be immunotitrated by addition of antibody 
to denatured human SCOT (H1-3). In contrast, the 
antibody to rat SCOT immunoprecipitated rat SCOT 
activity (R1 and 2). In our standard conditions for 
pulse-chase experiments, labelled protein is immuno- 
precipitated in a buffer of 10 mM Tris-HC1 (pH 7.5), 
2 mM EDTA, 0.1% SDS, 0.1% Triton X-100, and 10 
mM methionine. Human SCOT was not immunopre- 
cipitated by our anti-[human SCOT] antibody under 
these conditions determined by immunoblot analysis 
(data not shown), indicating that the antibody was not 
useful for pulse-chase experiments in our system. We 
conclude that the human SCOT antibody did not 
significantly react with native SCOT. 
Fig. 2. Immunoblot analysis with antiserum to recombinant hu- 
man SCOT. Immune sera were used 1/10000 dilution as the first 
antibodies. 5, 10, and 15/xg of rat heart muscle protein, 15/zg of 
rat liver protein, 5, 10, and 15/zg of human heart muscle protein, 
and 15 /zg of human liver protein were applied to lanes 1-8, 
respectively. Arrows indicate SCOT protein. Kaleidoscope 
Prestained Standards (Bio-Rad) were used as sizemarkers. 
3.5. Application of the antibody to human SCOT for 
diagnosis of SCOT deficiency 
We measured SCOT levels in the following sam- 
pies, using immunoblot analysis: fibroblasts from two 
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Fig. 3. Immunotitration a alysis. 1, 5 and 10 /xl of antiserum to 
SCOT were incubated with a fixed amount (12-20 /zg protein) 
of heart extract. We assayed SCOT activity in the supernatant 
following incubation with Protein A Sepharose. HI, H2 and H3: 
human heart extract was immunotitrated with anti-[human SCOT] 
antibody three times; R 1,2: rat heart extract was done with 
anti-[rat SCOT] antibody. 
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Fig. 4. Immunoblot analysis of fibroblasts and lymphocytes from controls and SCOT-deficient families. Each lane contains 30 /xg protein 
from fibroblasts or lymphocytes extracts. The first antibody was a mixture of two antisera, to human SCOT (10000-fold ilution) and to 
rat T2 (20000-fold ilution). Cont. indicates control fibroblasts or lymphocytes. GSI, GS2, GS3, and GS4 were SCOT-deficient patients. 
GS1 F and GS1 M were the father and the mother of GS1, respectively. GS2F and GS2M were the father and the mother of GS2 and his 
sibling GS3, respectively. Kaleidoscope Prestained Standards (Bio-Rad) were used as sizemarkers. 
controls, four SCOT-deficient patients (GS1, GS2, 
GS3, and GS4), and the parents of GS 1, and lympho- 
cytes from two controls and from GS2, his sibling 
GS3 and their parents (Fig. 4). A mixture of anti-[hu- 
man SCOT] antibody and anti-[rat T2] antibody was 
used as the first antibody. The bands corresponding 
to T2 were clearly seen with almost the same inten- 
sity in each lane of fibroblasts or in each lane of 
lymphocytes, providing internal standard for amounts 
of applied protein. ~ 52 kDa SCOT bands in control 
lymphocytes were more intense than those of control 
fibroblasts. This is in accordance with our previous 
observation that lymphocytes have about two-fold 
SCOT activity of control fibroblasts [8]. 
We have reported that the causal mutation in GS1 
was $283X [14]. $283X causes premature termina- 
tion and is incompatible with the production of nor- 
mal-sized SCOT message. A truncated 30.1 kDa 
SCOT protein is predicted but no such signal was 
detectable in this region in GS 1. Each of the parents 
of GS1 had SCOT bands (lanes GS1F and GS1M) of 
much lesser intensity than controls, as expected since 
both carry the $283X mutation. A faint background 
fragment is present at the position of normal SCOT 
in the sample from GSI, and serves as a negative 
control to which to compare samples from the other 
patients. Fibroblasts from GS2, GS3, and GS4 had no 
detectable SCOT cross reactive material (CRM). 
In analysis of GS2 family using lymphocytes, GS2 
and GS3 had no SCOT CRM. The parents (lanes 
GS2F and GS2M) had considerable SCOT protein, 
however, with lesser intensity than controls. This 
suggests that both parents are carriers of SCOT defi- 
ciency. 
4. Discussion 
We report the development of an antibody to 
human SCOT which is useful as a diagnostic tool for 
SCOT deficiency. The use of the antibody, as well as 
the human SCOT cDNAs which we recently cloned 
[14], will refine the diagnosis SCOT deficiency. 
A previously-reported polyclonal antibody to rat 
SCOT [16], did not crossreact with human SCOT. In 
contrast antibody to human SCOT which we report 
here crossreact with denatured rat SCOT in im- 
munoblots with almost the same affinity as with 
human SCOT, suggesting that denatured human and 
rat SCOT peptides hare common epitopes which are 
masked in the native polypeptides. 
156 X.-Q. Song et al. / Biochimica et Biophysica Acta 1360 (1997) 151-156 
To date, we have diagnosed 4 cases of SCOT 
deficiency ([7,8,15], and Wanders et al. unpublished). 
SCOT enzyme assay using fibroblasts and lympho- 
cytes is useful for diagnosis of SCOT deficiency [8]. 
However, background activity in the assay is high, 
making it difficult o precisely evaluate residual SCOT 
activities in fibroblasts or lymphocytes. For example, 
GS1 is homozygous for $283X [14], a mutation 
which is predicted to obliterate the function of SCOT, 
but SCOT activity in fibroblasts from patient GS1 
was observed to be 23% of control value [7]. One of 
our aims in developing antibody to human SCOT was 
to use it for immunotitration in precise evaluation of 
residual activity. Unfortunately, the antibody to dena- 
tured SCOT does not recognize the native SCOT 
protein. 
However, as shown in Fig. 4, the antibody is 
useful for immunoblot analysis. None of the four 
SCOT-deficient patients tested had detectable CRM. 
By densitometry we estimate that none had greater 
than one-tenth the amount of SCOT present in con- 
trol fibroblasts (data not shown) suggesting that their 
true residual SCOT activity is likely to be very low. 
Immunoblot analysis therefore provides complemen- 
tary information useful for evaluation of the severity 
of the defect, in addition to enzyme assay. Any point 
mutation at the active centers might affect activity 
but not protein mass and mutations outside the active 
centers might affect SCOT turnover, stability etc. 
Thus both activity assay and immunologic protein 
determination are useful to the understanding of the 
defects. Ultimately, mutation analysis and expression 
of mutant cDNAs will also be necessary in order to 
determine true SCOT residual activity with which to 
correlate the clinical features of the patient. 
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